According to the contract, Artgen Biotekh had to create a vaccine and pre -clinical trials and Natsimbio – clinical research and records. However, it did not eliminate common deficiencies, which led to the decision not to start clinical tests. In Rostec, it was clarified that cooperation could continue if the problems were solved. For example, in terms of the supply of components for the drug.
Despite difficulties, the holding does not refuse to create a single vaccine. The study continues on another technological platform with a new partner named unnamed. In the near future, it is expected to obtain permission to start clinical research.
Rostec stressed that existing disputes will not affect the conditions of the project. The basic emphasis is the safety and effectiveness of the future drug. If the tests are successful, the United Vaccine may simplify the prevention of two infections due to a single vaccine.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
